NAD Refers Advertising Claims from Cortec Corp. to FTC for Further Review
New York, NY – Jan. 5, 2015 – The National Advertising Division has referred to the Federal Trade Commission (FTC) advertising claims made by Cortec Corporation, the maker of vapor corrosion inhibiting (VCI) products, after the advertiser declined to participate in a self-regulatory review of its advertising claims.
NAD is an investigative unit of the advertising industry’s system of self-regulation. It is administered by the Council of Better Business Bureaus.
The decision to refer Cortec’s advertising claims follows an initial inquiry and a compliance review.
NAD opened its initial inquire after Cortec’s claims were challenged by Northern Technologies International Corporation, the maker of Zerust VCI products. The challenger took issue with a variety of claims made in e-mail communications with third-party distributors, including claims that the challenger’s VCI films did not “pass any standard test for corrosion protection,” that the challenger was “selling counterfeit product,” and that its VCI films were “failing due to outdated chemistry and a lack of quality control.”
NAD determined that the e-mail communications, directed to third-party distributors that sell the parties’ products to end users, fell within the definition of “national advertising” as outlined in NAD’s procedures. NAD found that Cortec did not provide a reasonable basis for the challenged claims and recommended Cortec discontinue the claims.
The advertiser disputed NAD’s jurisdiction, but said it “will take into account the NAD recommendations should it disseminate similar promotions or emails in the future.”
In December 2014, the challenger asserted that the advertiser continued to make claims similar to those challenged in the underlying proceeding and requested that NAD initiate a compliance proceeding.
In response to NAD’s compliance request, the advertiser stated that it did not agree to participate in either the underlying case or the compliance review.
NAD was disappointed that the advertiser declined to participate in the self-regulatory process. In light of the advertiser’s position, NAD, pursuant to Section 2.9 of the NAD/NARB Procedures, referred this matter to the FTC for possible law enforcement action.
Subscribe to the Ad Law Insights or Privacy Initiatives newsletters for an exclusive monthly analysis and insider perspectives on the latest trends and case decisions in advertising law and data privacy.
Latest Decisions
National Advertising Division Recommends Revolve Group Modify Social Media Posts to Clearly Disclose Material Connection to Influencers
New York, NY – January 29, 2025 – The National Advertising Division recommended Revolve modify influencer posts to clearly and conspicuously disclose the material connections between Revolve and influencers in its product gifting program.
National Advertising Division Recommends Bullfrog Modify or Discontinue Certain Comparative Superiority Claims for its Bullfrog Spas
New York, NY – January 29, 2025 – The National Advertising Division recommended that Bullfrog discontinue certain claims promoting the personalization, power, energy efficiency, and durability of its Bullfrog spas as compared to “conventional” hot tubs.
Direct Selling Self-Regulatory Council Refers Ardyss Earnings and Product Performance Claims to the FTC and Nevada Attorney General’s Office
McLean, VA – January 28, 2025 – The Direct Selling Self-Regulatory Council (DSSRC) referred ArdyssLife to the Federal Trade Commission (FTC) and the Nevada Attorney General’s Office for possible enforcement action after Ardyss failed to confirm intent to comply with DSSRC recommendations to discontinue...
National Advertising Division Recommends Olly Discontinue or Modify Certain Claims for its Kids Chillax Product; Olly to Appeal
New York, NY – January 27, 2025 – BBB National Programs’ National Advertising Division recommended that Olly discontinue or modify certain claims concerning its Kids Chillax dietary supplement’s ability to support calm and relaxed moods in children, as well as claims for Olly’s previous formulation of its Kids...